Chloral Hydrate's Impact on Brain Development: From Clinical Safety to Molecular Mechanisms

Pengyi Deng1, Chenghao Zhu1, Jie Zhang1

  • 1The School of Pediatrics, Hengyang Medical School, University of South China (Hunan Children's Hospital), Changsha, Hunan, 410007, People's Republic of China.

PubMed

Insights

Chloral hydrate is a vital pediatric sedative, but prolonged use may negatively impact children's intelligence quotient (PIQ) and neurodevelopment. Further research is needed to understand its effects on the developing central nervous system (CNS).

Area of Science:

  • Pediatric pharmacology
  • Neurodevelopmental toxicology
  • Clinical neuroscience

Background:

  • Chloral hydrate is a first-line sedative in pediatric practice, essential for outpatient procedures.
  • Its impact on the developing central nervous system (CNS) in children is not well understood.
  • Children's developing brains are more vulnerable due to immature blood-brain barrier (BBB) and high neuronal plasticity.

Purpose of the Study:

  • To synthesize current evidence on chloral hydrate's effects on pediatric neurodevelopment.
  • To identify potential molecular mechanisms underlying these effects.
  • To highlight clinical safety concerns regarding long-term administration.

Main Methods:

  • Review and synthesis of existing clinical observations and molecular mechanism studies.
  • Analysis of the correlation between chloral hydrate usage duration and pediatric intelligence quotient (PIQ).
  • Proposed disruption pathways involving NMDA receptors, GABA receptors, and MEK-ERK signaling.

Main Results:

  • A negative correlation exists between chloral hydrate duration and pediatric intelligence quotient (PIQ).
  • Prolonged use may impair non-verbal abilities, impacting overall cognitive function.
  • Potential neurodevelopmental disruption via NMDA, GABA, and MEK-ERK pathways is proposed.

Conclusions:

  • Caution is advised regarding long-term chloral hydrate use in children.
  • Long-term follow-up of exposed children for cognitive and neurodevelopmental monitoring is recommended.
  • Future research should focus on prospective studies with neuroimaging and biomarkers.

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
179
Teratogenicity01:07

Teratogenicity

The ability of a drug to produce structural deformations and functional abnormalities in the developing embryo or the fetus is called teratogenicity, and the drug producing this effect is known as a teratogen. Teratogenic effects include stillbirth, miscarriage, intrauterine growth restriction, and neurocognitive delay. A teratogen may affect the embryo at different stages of development, which is important in determining the type and extent of the damage. During blastocyst formation, the early...
3.9K
Factors Affecting Drug Response: Overview01:21

Factors Affecting Drug Response: Overview

When it comes to infants and young children, they are typically administered smaller doses of medication in comparison to adults. This is primarily because their organ functions still need to fully develop, meaning their bodies are not as efficient at metabolizing or eliminating drugs. Additionally, their blood-brain barrier is more permeable than in adults. As a result, high concentrations of drugs can easily penetrate the central nervous system (CNS), potentially leading to neurological...
2.8K
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.6K
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
247
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
232